Valuation: Omeros Corporation

Market Cap 857M 745M 695M 638M 1.2B 81.68B 1.22B 8.2B 3.21B 40.73B 3.22B 3.15B 134B P/E 2026 *
-197x
P/E 2027 * 154x
Enterprise Value 857M 745M 695M 638M 1.2B 81.68B 1.22B 8.2B 3.21B 40.73B 3.22B 3.15B 134B EV / Sales 2026 *
12.6x
EV / Sales 2027 * 5.99x
Free-Float
96.44%
Yield 2026 *
-
Yield 2027 * -
1 day+6.08%
1 week+28.29%
Current month+6.08%
1 month+35.34%
3 months-16.60%
6 months+7.17%
Current year-26.87%
1 week 10.58
Extreme 10.58
12.59
1 month 9.12
Extreme 9.12
12.59
Current year 6.7
Extreme 6.7023
17.63
1 year 3.44
Extreme 3.435
17.65
3 years 0.92
Extreme 0.92
17.65
5 years 0.92
Extreme 0.92
17.65
10 years 0.92
Extreme 0.92
27.09
Manager TitleAgeSince
Chief Executive Officer 67 1994-06-15
Director of Finance/CFO 62 2024-06-29
Chief Tech/Sci/R&D Officer 70 2019-10-31
Director TitleAgeSince
Chairman 67 1994-06-15
Director/Board Member 86 1994-12-31
Director/Board Member 72 1994-12-31
Date Insider Type Main position Quantity % Market Cap.
7/22/26 Free

Chief Financial Officer

105,000 0.1451%
7/22/26 Free

General Counsel

105,000 0.1451%
7/22/26 Free

Chief Executive Officer

1,000,000 1.3817%
Change 5-day change 1-year change 3-year change Capi.($)
+6.08%+28.29%+247.92%+217.97% 857M
+0.05%+2.80%+38.17%+74.12% 56.54B
-3.06%-10.22%+23.62%+58.59% 53.6B
+1.84%+3.27%-14.06%-12.13% 22.91B
-0.15%-7.92%-9.42%+352.23% 21.37B
+0.15%-0.77%+23.76%-11.52% 20.27B
-0.67%-1.73%+33.09%-31.09% 17.56B
-1.45%-7.24%+17.67%+563.14% 14.75B
+9.91%+2.64%+188.84%+326.19% 13.53B
+3.83%-0.56%+47.77%+170.70% 13.33B
Average +1.65%+0.40%+59.74%+170.82% 23.47B
Weighted average by Cap. +0.16%-1.62%+32.50%+123.48%

Financials

2026 *2027 *
Net sales 67.83M 58.95M 55.04M 50.53M 95.27M 6.47B 96.93M 649M 254M 3.22B 255M 249M 10.63B 143M 124M 116M 107M 201M 13.64B 204M 1.37B 536M 6.8B 538M 526M 22.44B
Net income -12.1M -10.52M -9.82M -9.01M -16.99M -1.15B -17.29M -116M -45.34M -575M -45.45M -44.44M -1.9B 1.25M 1.09M 1.01M 931K 1.76M 119M 1.79M 11.96M 4.68M 59.42M 4.7M 4.59M 196M
Net Debt - -
Logo Omeros Corporation
Omeros Corporation is a clinical-stage biopharmaceutical company. The Company focuses on discovering, developing, and commercializing first-in-class small-molecule and protein therapeutics for both large-market and orphan indications, with a particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. Its clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program. Its commercial product, YARTEMLEA, is the approved inhibitor of the lectin pathway of complement. YARTEMLEA is used for the treatment of TA-TMA in adults and in children ages two years and older. YARTEMLEA selectively inhibits MASP-2, blocking pathway activation while preserving classical and alternative complement pathway functions.
Employees
175
Date Price Change Volume
26-08-03 $12.56 +6.08% 1,445,442
26-07-31 $11.84 -0.75% 1,309,589
26-07-30 $11.93 +2.23% 1,331,086
26-07-29 $11.67 +3.46% 1,686,053
26-07-28 $11.28 -0.53% 2,222,452
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
11.84USD
Average target price
33.00USD
Spread / Average Target
+178.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OMER Stock